---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Access and distribution"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Access and distribution. Topics: Current access: clinical trials only; no expanded access; Commercial build-out: field medical, market access, and strategic account teams; Treatment centers: HDSA Centers of Excellence and stereotactic surgical infrastructure; Neurosurgical administration requirements; 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/access-and-distribution"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Current access: clinical trials only; no expanded access

> “After careful consideration, uniQure has decided not to provide expanded access to any of our investigational gene therapies at this time.”
> “Delivery and administration of the investigational therapy outside of the clinical trial setting must be feasible, including ensuring that there are appropriate healthcare facilities available to administer the investigational therapy, manage potential side effects, and ensure ongoing follow-up as needed.”

Source: [uniQure expanded access policy (2024)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/uniQure_Expanded-Access-Policy_05June24.pdf)

<a id="topic-2.1.2.11-2"></a>

### Commercial build-out: field medical, market access, and strategic account teams

> “The Company continues to advance its launch readiness activities, including the build out of its field medical, market access, and strategic account teams as well as engagement with U.S. Huntington’s disease treatment centers.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.1.2.11-3"></a>

### Treatment centers: HDSA Centers of Excellence and stereotactic surgical infrastructure

> “Established HDSA COEs and surgical infrastructure are well positioned to serve HD patients, with ongoing efforts to prioritize key treatment centers for launch”
> “Heat Map of Clearpoint Neuro Capable Facilities and HDSA COEs by Patient Volume”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.1.2.11-4"></a>

### Neurosurgical administration requirements

> “AMT-130 is administered via a standard stereotactic procedure that can be broadly performed.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

> “Moreover, certain of our delivery modalities, such as direct delivery of product candidates to the brain, may require significant time and physician ability and skill.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “AMT-130 was infused into two specific brain regions (caudate and putamen, together known as the striatum) under general anesthesia at a surgical center that specializes in these procedures.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

<a id="topic-2.1.2.11-5"></a>

### Manufacturing supply through Genezen

> “Following the Lexington Transaction, Genezen may experience challenges in adapting the Lexington Facility to meet the manufacturing and supply needs for products other than HEMGENIX as a result of capacity and resource constraints, or its inability to adapt to new manufacturing processes, among other challenges.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “This transaction achieves these objectives by unlocking significant cost savings while maintaining preferential access to world-class gene therapy manufacturing.”

Source: [uniQure press release, sale of manufacturing facility to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-sale-commercial-manufacturing-facility-genezen)

<a id="topic-2.1.2.11-6"></a>

### Specialty distribution, risk evaluation and mitigation strategy, and payer coverage

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
